Treatment for Primary Syphilis

Primary Treatment Regimen

The Centers for Disease Control and Prevention (CDC) recommends benzathine penicillin G 2.4 million units IM as a single dose for primary syphilis, based on over 40 years of clinical experience and recent high-quality randomized controlled trials 1, 2, 3.
This single-dose regimen has been validated across multiple CDC guidelines and remains the gold standard for primary syphilis treatment 2, 3, 4, 5.

The CDC recommends testing for HIV infection immediately in all patients with syphilis, as coinfection affects monitoring frequency and may increase risk for neurologic complications 2, 3, 6.
If HIV-positive, the same single-dose treatment is still recommended, but follow-up intervals change from 6-month to 3-month intervals 3, 5, 6.

For patients with a documented penicillin allergy, the CDC recommends doxycycline 100 mg orally twice daily for 14 days as the preferred alternative 2, 3, 4.
Tetracycline 500 mg orally four times daily for 14 days is an option, but compliance is typically worse due to gastrointestinal side effects 2, 4.

Clinical and serologic evaluation at 6 and 12 months after treatment using nontreponemal tests (RPR or VDRL) is recommended 3, 6.
A successful response is defined as a fourfold decline in nontreponemal titer within 6-12 months 3, 4, 6.
If HIV-positive, evaluation at 3, 6, 9, and 12 months instead is recommended 3, 5, 6.

Treatment failure should be suspected if nontreponemal titers fail to decline fourfold within 6 months after therapy 3, 4.
Clinical signs or symptoms persisting or recurring also indicate treatment failure 3, 7.
A sustained fourfold increase in titer compared to baseline is another indicator of treatment failure 3, 4.

All sexual contacts from the past 3 months should be evaluated and treated presumptively 2, 3.
Partners should receive the same treatment regimen even if asymptomatic 2, 3.

Treponemal tests (FTA-ABS, TP-PA) should not be used to monitor treatment response, as they remain positive for life and do not correlate with disease activity 6.
Titers between different test types (VDRL vs RPR) should not be compared, as they are not directly comparable 6.
Persistent low-titer reactivity should not be assumed to indicate treatment failure, as approximately 15-25% of patients remain "serofast" with low unchanging titers despite cure 1, 4, 6.